Clinical trial · no report yet · Phase 2
KEYNOTE-B61
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
- NCT04704219 ↗
- Completed
- Merck Sharp & Dohme LLC
- 34 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 14 | |
| YouTube | 13 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab; Lenvatinib
- Arms
- Pembrolizumab + Lenvatinib · Experimental
- Enrollment
- 160
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Feb 23, 2021
- Primary completion
- Jan 27, 2025
- Results posted
- Yes
- Registry record
- NCT04704219 · updated Dec 3, 2025
Publications
linked from the registry- Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. PubMed 37451291
- Voss MH, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Nalbandian T, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Cornell J, Sharma M, Burgents JE, Albiges L. First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. Eur Urol. 2025 Dec;88(6):614-624. doi: 10.1016/j.eururo.2025.05.019. Epub 2025 Jul 24. PubMed 40707309